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who should not operate if there is
persistent N2 disease after induction
therapy, the referent value, negative
predictive value, is most important. It
is defined as the number of patients
without N2 disease who are identified
by the test (true-negative results) di-
vided by the total number of patients
identified by the test to be without N2
disease (true-negative plus false-nega-
tive results). A high negative predic-
tive value (few false-negative results)
permits the surgeon to confidently
use the results of remediastinoscopy
to plan further surgical intervention.
Statement 4: ‘‘Sensitivity truly
starts at 50% (a test of no sensitivity
or equipoise), not 0%.’’
A referent value has merit through-
out its range. A test with 0% sensitiv-
ity is unable to identify any patient
with disease; one with 100% sensi-
tivity identifies every patient with
disease. Equipoise is equality of distri-
bution, equilibrium, or counterbal-
ance. Although we cannot verify this,
we believe the writers might be con-
fusing the referent value sensitivity
with the area beneath the receiver op-
erator characteristic, expressed as the
C statistic, which is a graph of sensitiv-
ity versus 1 minus specificity. An area
of 0.5 (C ¼ 0.5) might be interpreted
as ‘‘equipoise’’ because this is the ex-
pected relationship between groups
whose testing has produced com-
pletely random results.
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Reply to the Editor:
We appreciate the interest that Ram-
araj has shown in our article, and we
are deeply honored by his comments.1
He possesses expertise in a broad area
of medical science, not only in ische-
mic cardiomyopathy, the subject for
our study.
As Ramaraj points out, hyperkale-
mia induced by spironolactone is
a life-threatening side effect clinicians
should look out for. On the other
hand, as cardiovascular surgeons in-
volved in clinical practice, we have
focused on redilatation of the left ven-
tricle in the chronic stage of left
ventricular restoration (LVR) surgery,
searching for any treatment to prevent
it. Although the precise mechanism of
redilatation has not been elucidated,
fibrosis occurred both in border zone
and remote area of plicated infarcted
area in our study, and it was alleviated
by spironolactone. It is well known
that activation of renin-angiotensin-
aldosterone system (RAAS) induces
cardiac fibrosis in autocrine/paracrine
manner. We thought it is possible
that RAAS is one mechanism of
redilatation. Angiotensin-converting
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To the Editor:
Tsukashita et al1 have performed an
excellent experimental study to show
that spironolactone alleviates remodel-
ing after left ventricular restoration.
When experimental studies are
translated into clinical practice, great
caution should be maintained. Previ-
ous clinical studies on spironolactone
showed a major impact on the pre-
scribing patterns of the doctors. After
the publication of the RALES study,
there was an enormous increase in
the prescription and usage of spirono-
lactone in the late 1990s, leading to
increased hospitalizations mostly due
to hyperkalemia.2 This was attributed
to lack of clinical and laboratory
monitoring, increased doses in pa-
tients with diabetes mellitus, renal
dysfunction, left ventricular ejection
fraction<20%, and elderly patients.2
Approximately 7.5 million of the
elderly patients in the United States
have a glomerular filtration rate <
60 mL/min, and in these patients, spi-
ronolactone causes increased adverse
reactions.3 Microalbuminuria is
a risk factor for heart failure with pre-
vious myocardial ischemia, and spiro-
nolactone has been demonstrated to
reduce microalbuminuria when added
to angiotensin-converting enzyme
inhibitors.4,5
Although spironolactone improves
heart failure symptoms and decreases
microalbuminuria, it should be used
in a selected group of patients. We
need further clinical studies that evalu-
ate the side effect profile to show the
same benefit in humans for alleviating
remodeling following the success of
the experimental study by Tsukashita
et al.1
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